Generic placeholder image

Current Pharmaceutical Biotechnology

Author(s): Roghayeh Nouri, Alka Hasani, Mohammad Asgharzadeh, Fatemeh Yeganeh Sefidan, Fatemeh Hemmati and Mohammad Ahangarzadeh Rezaee*

DOI: 10.2174/1389201023666220307112413

DownloadDownload PDF Flyer Cite As
Roles of Gut Microbiota in Colorectal Carcinogenesis Providing a Perspective for Early Diagnosis and Treatment

Page: [1569 - 1580] Pages: 12

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Colorectal cancer (CRC) is the third most prevalent malignant neoplasm in the world. CRC is influenced by both environmental and genetic factors. Through toxin-mediated DNA damage and the promotion of persistent dysregulated inflammation, the gut microbiota plays a crucial role in the development of CRC. In this review, we discussed the correlation between the bacterial microbiota and CRC carcinogenesis as well as the mechanism by which Streptococcus bovis/gallolyticus, Fusobacterium nucleatum, Bacteroides fragilis, and Escherichia coli can cause CRC.

Keywords: Gut microbiota, bacteria, colorectal cancer, carcinogenesis, inflammation, genotoxicity.

Graphical Abstract

[1]
Saus, E.; Iraola-Guzmán, S.; Willis, J.R.; Brunet-Vega, A.; Gabaldón, T. Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential. Mol. Aspects Med., 2019, 69, 93-106.
[http://dx.doi.org/10.1016/j.mam.2019.05.001] [PMID: 31082399]
[2]
Bundgaard-Nielsen, C.; Baandrup, U.T.; Nielsen, L.P.; Sørensen, S. The presence of bacteria varies between colorectal adenocarcinomas, precursor lesions and non-malignant tissue. BMC Cancer, 2019, 19(1), 399.
[http://dx.doi.org/10.1186/s12885-019-5571-y] [PMID: 31035942]
[3]
Al-Sohaily, S.; Biankin, A.; Leong, R.; Kohonen-Corish, M.; Warusavitarne, J. Molecular pathways in colorectal cancer. J. Gastroenterol. Hepatol., 2012, 27(9), 1423-1431.
[http://dx.doi.org/10.1111/j.1440-1746.2012.07200.x] [PMID: 22694276]
[4]
Vivarelli, S.; Salemi, R.; Candido, S.; Falzone, L.; Santagati, M.; Stefani, S.; Torino, F.; Banna, G.L.; Tonini, G.; Libra, M. Gut microbiota and cancer: From pathogenesis to therapy. Cancers (Basel), 2019, 11(1), 38.
[http://dx.doi.org/10.3390/cancers11010038] [PMID: 30609850]
[5]
Koliarakis, I.; Messaritakis, I.; Nikolouzakis, T.K.; Hamilos, G.; Souglakos, J.; Tsiaoussis, J. Oral bacteria and intestinal dysbiosis in colo-rectal cancer. Int. J. Mol. Sci., 2019, 20(17), 4146.
[http://dx.doi.org/10.3390/ijms20174146] [PMID: 31450675]
[6]
Chen, G.Y. The role of the gut microbiome in colorectal cancer. Clin. Colon Rectal Surg., 2018, 31(3), 192-198.
[http://dx.doi.org/10.1055/s-0037-1602239] [PMID: 29720905]
[7]
Kong, F.; Cai, Y. Study insights into gastrointestinal cancer through the gut microbiota. BioMed Res. Int., 2019, 2019, 8721503.
[http://dx.doi.org/10.1155/2019/8721503] [PMID: 31341907]
[8]
Chen, J.; Domingue, J.C.; Sears, C.L. Microbiota dysbiosis in select human cancers: evidence of association and causality. In: Semin. Im-munol; Elsevier, 2017, pp. 25-34.
[http://dx.doi.org/10.1016/j.smim.2017.08.001]
[9]
Gao, R.; Wang, Z.; Li, H.; Cao, Z.; Gao, Z.; Chen, H.; Zhang, X.; Pan, D.; Yang, R.; Zhong, H.; Shen, R.; Yin, L.; Jia, Z.; Shen, T.; Qin, N.; Hu, Z.; Qin, H. Gut microbiota dysbiosis signature is associated with the colorectal carcinogenesis sequence and improves the diagnosis of colorectal lesions. J. Gastroenterol. Hepatol., 2020, 35(12), 2109-2121.
[http://dx.doi.org/10.1111/jgh.15077] [PMID: 32337748]
[10]
Vacante, M.; Ciuni, R.; Basile, F.; Biondi, A. Gut microbiota and colorectal cancer development: A closer look to the adenoma-carcinoma sequence. Biomedicines, 2020, 8(11), 489.
[http://dx.doi.org/10.3390/biomedicines8110489] [PMID: 33182693]
[11]
Haghi, F.; Goli, E.; Mirzaei, B.; Zeighami, H. The association between fecal enterotoxigenic B. fragilis with colorectal cancer. BMC Cancer, 2019, 19(1), 879.
[http://dx.doi.org/10.1186/s12885-019-6115-1] [PMID: 31488085]
[12]
Kostic, A.D.; Chun, E.; Robertson, L.; Glickman, J.N.; Gallini, C.A.; Michaud, M.; Clancy, T.E.; Chung, D.C.; Lochhead, P.; Hold, G.L.; El-Omar, E.M.; Brenner, D.; Fuchs, C.S.; Meyerson, M.; Garrett, W.S. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe, 2013, 14(2), 207-215.
[http://dx.doi.org/10.1016/j.chom.2013.07.007] [PMID: 23954159]
[13]
Thiele Orberg, E.; Fan, H.; Tam, A.J.; Dejea, C.M.; Destefano Shields, C.E.; Wu, S.; Chung, L.; Finard, B.B.; Wu, X.; Fathi, P.; Ganguly, S.; Fu, J.; Pardoll, D.M.; Sears, C.L.; Housseau, F. The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine co-lon tumorigenesis. Mucosal Immunol., 2017, 10(2), 421-433.
[http://dx.doi.org/10.1038/mi.2016.53] [PMID: 27301879]
[14]
Bonnet, M.; Buc, E.; Sauvanet, P.; Darcha, C.; Dubois, D.; Pereira, B.; Déchelotte, P.; Bonnet, R.; Pezet, D.; Darfeuille-Michaud, A. Coloni-zation of the human gut by E. coli and colorectal cancer risk. Clin. Cancer Res., 2014, 20(4), 859-867.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-1343] [PMID: 24334760]
[15]
Lopès, A.; Billard, E.; Casse, A.H.; Villéger, R.; Veziant, J.; Roche, G.; Carrier, G.; Sauvanet, P.; Briat, A.; Pagès, F.; Naimi, S.; Pezet, D.; Barnich, N.; Dumas, B.; Bonnet, M. Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immu-notherapy resistance in colorectal cancer. Int. J. Cancer, 2020, 146(11), 3147-3159.
[http://dx.doi.org/10.1002/ijc.32920] [PMID: 32037530]
[16]
Wei, Z.; Cao, S.; Liu, S.; Yao, Z.; Sun, T.; Li, Y.; Li, J.; Zhang, D.; Zhou, Y. Could gut microbiota serve as prognostic biomarker associat-ed with colorectal cancer patients’ survival? A pilot study on relevant mechanism. Oncotarget, 2016, 7(29), 46158-46172.
[http://dx.doi.org/10.18632/oncotarget.10064] [PMID: 27323816]
[17]
Temraz, S.; Nassar, F.; Nasr, R.; Charafeddine, M.; Mukherji, D.; Shamseddine, A. Gut microbiome: A promising biomarker for immuno-therapy in colorectal cancer. Int. J. Mol. Sci., 2019, 20(17), 4155.
[http://dx.doi.org/10.3390/ijms20174155] [PMID: 31450712]
[18]
Ai, D.; Pan, H.; Han, R.; Li, X.; Liu, G.; Xia, L.C. Using decision tree aggregation with random forest model to identify gut microbes asso-ciated with colorectal cancer. Genes (Basel), 2019, 10(2), 112.
[http://dx.doi.org/10.3390/genes10020112] [PMID: 30717284]
[19]
Flemer, B.; Lynch, D.B.; Brown, J.M.; Jeffery, I.B.; Ryan, F.J.; Claesson, M.J.; O’Riordain, M.; Shanahan, F.; O’Toole, P.W. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut, 2017, 66(4), 633-643.
[http://dx.doi.org/10.1136/gutjnl-2015-309595] [PMID: 26992426]
[20]
Wu, J.; Li, Q.; Fu, X. Fusobacterium nucleatum contributes to the carcinogenesis of colorectal cancer by inducing inflammation and sup-pressing host immunity. Transl. Oncol., 2019, 12(6), 846-851.
[http://dx.doi.org/10.1016/j.tranon.2019.03.003] [PMID: 30986689]
[21]
Wei, T-T.; Lin, Y-T.; Tseng, R-Y.; Shun, C-T.; Lin, Y-C.; Wu, M-S.; Fang, J-M.; Chen, C-C. Prevention of colitis and colitis-associated colorectal cancer by a novel polypharmacological histone deacetylase inhibitor. Clin. Cancer Res., 2016, 22(16), 4158-4169.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-2379] [PMID: 27528734]
[22]
Mármol, I.; Sánchez-de-Diego, C.; Pradilla Dieste, A.; Cerrada, E.; Rodriguez Yoldi, M.J. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int. J. Mol. Sci., 2017, 18(1), 197.
[http://dx.doi.org/10.3390/ijms18010197] [PMID: 28106826]
[23]
Gao, Z.; Guo, B.; Gao, R.; Zhu, Q.; Qin, H. Microbiota disbiosis is associated with colorectal cancer. Front. Microbiol., 2015, 6, 20.
[http://dx.doi.org/10.3389/fmicb.2015.00020] [PMID: 25699023]
[24]
Lu, Y.; Chen, J.; Zheng, J.; Hu, G.; Wang, J.; Huang, C.; Lou, L.; Wang, X.; Zeng, Y. Mucosal adherent bacterial dysbiosis in patients with colorectal adenomas. Sci. Rep., 2016, 6(1), 26337.
[http://dx.doi.org/10.1038/srep26337] [PMID: 27194068]
[25]
Candela, M.; Turroni, S.; Biagi, E.; Carbonero, F.; Rampelli, S.; Fiorentini, C.; Brigidi, P. Inflammation and colorectal cancer, when micro-biota-host mutualism breaks. World J. Gastroenterol., 2014, 20(4), 908-922.
[http://dx.doi.org/10.3748/wjg.v20.i4.908] [PMID: 24574765]
[26]
Xie, X.; He, Y.; Li, H.; Yu, D.; Na, L.; Sun, T.; Zhang, D.; Shi, X.; Xia, Y.; Jiang, T.; Rong, S.; Yang, S.; Ma, X.; Xu, G. Effects of prebiot-ics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients. Nutrition, 2019, 61, 132-142.
[http://dx.doi.org/10.1016/j.nut.2018.10.038] [PMID: 30711862]
[27]
Gao, R.; Kong, C.; Li, H.; Huang, L.; Qu, X.; Qin, N.; Qin, H. Dysbiosis signature of mycobiota in colon polyp and colorectal cancer. Eur. J. Clin. Microbiol. Infect. Dis., 2017, 36(12), 2457-2468.
[http://dx.doi.org/10.1007/s10096-017-3085-6] [PMID: 28821976]
[28]
Sobhani, I.; Tap, J.; Roudot-Thoraval, F.; Roperch, J.P.; Letulle, S.; Langella, P.; Corthier, G.; Tran Van Nhieu, J.; Furet, J.P. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One, 2011, 6(1), e16393.
[http://dx.doi.org/10.1371/journal.pone.0016393] [PMID: 21297998]
[29]
Ganesan, K.; Guo, S.; Fayyaz, S.; Zhang, G.; Xu, B. Targeting programmed Fusobacterium nucleatum Fap2 for colorectal cancer therapy. Cancers (Basel), 2019, 11(10), 1592.
[http://dx.doi.org/10.3390/cancers11101592] [PMID: 31635333]
[30]
Swidsinski, A.; Khilkin, M.; Kerjaschki, D.; Schreiber, S.; Ortner, M.; Weber, J.; Lochs, H. Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology, 1998, 115(2), 281-286.
[http://dx.doi.org/10.1016/S0016-5085(98)70194-5] [PMID: 9679033]
[31]
Gold, J.S.; Bayar, S.; Salem, R.R. Association of Streptococcus bovis bacteremia with colonic neoplasia and extracolonic malignancy. Arch. Surg., 2004, 139(7), 760-765.
[http://dx.doi.org/10.1001/archsurg.139.7.760] [PMID: 15249410]
[32]
Liu, I.L.; Tsai, C-H.; Hsu, C-H.; Hu, J-M.; Chen, Y-C.; Tian, Y-F.; You, S-L.; Chen, C-Y.; Hsiao, C-W.; Lin, C-Y.; Chou, Y.C.; Sun, C.A. Helicobacter pylori infection and the risk of colorectal cancer: a nationwide population-based cohort study. QJM, 2019, 112(10), 787-792.
[http://dx.doi.org/10.1093/qjmed/hcz157] [PMID: 31250012]
[33]
Li, Y-Y.; Ge, Q-X.; Cao, J.; Zhou, Y-J.; Du, Y-L.; Shen, B.; Wan, Y-J.Y.; Nie, Y-Q. Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients. World J. Gastroenterol., 2016, 22(11), 3227-3233.
[http://dx.doi.org/10.3748/wjg.v22.i11.3227] [PMID: 27004000]
[34]
Saeed, A.; Eshrat, F.F.; Umar, S.; Saeed, A. The duplex interaction of microbiome with chemoradiation and immunotherapy: potential implications for colorectal cancer. Curr. Colorectal Cancer Rep., 2019, 15(3), 98-104.
[http://dx.doi.org/10.1007/s11888-019-00435-1] [PMID: 31680787]
[35]
Collins, D.; Hogan, A.M.; Winter, D.C. Microbial and viral pathogens in colorectal cancer. Lancet Oncol., 2011, 12(5), 504-512.
[http://dx.doi.org/10.1016/S1470-2045(10)70186-8] [PMID: 21067973]
[36]
Gagnière, J.; Raisch, J.; Veziant, J.; Barnich, N.; Bonnet, R.; Buc, E.; Bringer, M-A.; Pezet, D.; Bonnet, M. Gut microbiota imbalance and colorectal cancer. World J. Gastroenterol., 2016, 22(2), 501-518.
[http://dx.doi.org/10.3748/wjg.v22.i2.501] [PMID: 26811603]
[37]
Purcell, R.V.; Pearson, J.; Aitchison, A.; Dixon, L.; Frizelle, F.A.; Keenan, J.I. Colonization with enterotoxigenic Bacteroides fragilis is associated with early-stage colorectal neoplasia. PLoS One, 2017, 12(2), e0171602.
[http://dx.doi.org/10.1371/journal.pone.0171602] [PMID: 28151975]
[38]
Arthur, J.C.; Jobin, C. The complex interplay between inflammation, the microbiota and colorectal cancer. Gut Microbes, 2013, 4(3), 253-258.
[http://dx.doi.org/10.4161/gmic.24220] [PMID: 23549517]
[39]
Goodwin, A.C.; Destefano Shields, C.E.; Wu, S.; Huso, D.L.; Wu, X.; Murray-Stewart, T.R.; Hacker-Prietz, A.; Rabizadeh, S.; Woster, P.M.; Sears, C.L.; Casero, R.A. Jr Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc. Natl. Acad. Sci. USA, 2011, 108(37), 15354-15359.
[http://dx.doi.org/10.1073/pnas.1010203108] [PMID: 21876161]
[40]
Yang, Z.; Ji, G. Fusobacterium nucleatum-positive colorectal cancer. Oncol. Lett., 2019, 18(2), 975-982.
[PMID: 31423156]
[41]
Kumar, R.; Herold, J.L.; Taylor, J.; Xu, J.; Xu, Y. Variations among Streptococcus gallolyticus subsp. gallolyticus strains in connection with colorectal cancer. Sci. Rep., 2018, 8(1), 1514.
[http://dx.doi.org/10.1038/s41598-018-19941-7] [PMID: 29367658]
[42]
Paritsky, M.; Pastukh, N.; Brodsky, D.; Isakovich, N.; Peretz, A. Association of Streptococcus bovis presence in colonic content with ad-vanced colonic lesion. World J. Gastroenterol., 2015, 21(18), 5663-5667.
[http://dx.doi.org/10.3748/wjg.v21.i18.5663] [PMID: 25987793]
[43]
Tsai, C-E.; Chiu, C-T.; Rayner, C.K.; Wu, K-L.; Chiu, Y-C.; Hu, M-L.; Chuah, S-K.; Tai, W-C.; Liang, C-M.; Wang, H-M. Associated fac-tors in Streptococcus bovis bacteremia and colorectal cancer. Kaohsiung J. Med. Sci., 2016, 32(4), 196-200.
[http://dx.doi.org/10.1016/j.kjms.2016.03.003] [PMID: 27185602]
[44]
Abdulamir, A.S.; Hafidh, R.R.; Abu Bakar, F. The association of Streptococcus bovis/gallolyticus with colorectal tumors: the nature and the underlying mechanisms of its etiological role. J. Exp. Clin. Cancer Res., 2011, 30(1), 11.
[http://dx.doi.org/10.1186/1756-9966-30-11] [PMID: 21247505]
[45]
Abdulamir, A.S.; Hafidh, R.R.; Bakar, F.A. Molecular detection, quantification, and isolation of Streptococcus gallolyticus bacteria colo-nizing colorectal tumors: Inflammation-driven potential of carcinogenesis via IL-1, COX-2, and IL-8. Mol. Cancer, 2010, 9(1), 249.
[http://dx.doi.org/10.1186/1476-4598-9-249] [PMID: 20846456]
[46]
Ellmerich, S.; Djouder, N.; Schöller, M.; Klein, J-P. Production of cytokines by monocytes, epithelial and endothelial cells activated by Streptococcus bovis. Cytokine, 2000, 12(1), 26-31.
[http://dx.doi.org/10.1006/cyto.1999.0521] [PMID: 10623439]
[47]
Lucas, C.; Barnich, N.; Nguyen, H.T.T. Microbiota, inflammation and colorectal cancer. Int. J. Mol. Sci., 2017, 18(6), 1310.
[http://dx.doi.org/10.3390/ijms18061310] [PMID: 28632155]
[48]
Abdulamir, A.S.; Hafidh, R.R.; Mahdi, L.K.; Al-jeboori, T.; Abubaker, F. Investigation into the controversial association of Streptococcus gallolyticus with colorectal cancer and adenoma. BMC Cancer, 2009, 9(1), 403.
[http://dx.doi.org/10.1186/1471-2407-9-403] [PMID: 19925668]
[49]
Darjee, R.; Gibb, A.P. Serological investigation into the association between Streptococcus bovis and colonic cancer. J. Clin. Pathol., 1993, 46(12), 1116-1119.
[http://dx.doi.org/10.1136/jcp.46.12.1116] [PMID: 8282836]
[50]
Feng, Y.Y.; Zeng, D.Z.; Tong, Y.N.; Lu, X.X.; Dun, G.D.; Tang, B.; Zhang, Z.J.; Ye, X.L.; Li, Q.; Xie, J.P.; Mao, X.H. Alteration of mi-croRNA-4474/4717 expression and CREB-binding protein in human colorectal cancer tissues infected with Fusobacterium nucleatum. PLoS One, 2019, 14(4), e0215088.
[http://dx.doi.org/10.1371/journal.pone.0215088] [PMID: 30951563]
[51]
Lee, S.A.; Liu, F.; Riordan, S.M.; Lee, C.S.; Zhang, L. Global investigations of Fusobacterium nucleatum in human colorectal cancer. Front. Oncol., 2019, 9, 566.
[http://dx.doi.org/10.3389/fonc.2019.00566] [PMID: 31334107]
[52]
Shariati, A.; Razavi, S.; Ghaznavi-Rad, E.; Jahanbin, B.; Akbari, A.; Norzaee, S.; Darban-Sarokhalil, D. Association between colorectal cancer and Fusobacterium nucleatum and Bacteroides fragilis bacteria in Iranian patients: A preliminary study. Infect. Agent. Cancer, 2021, 16(1), 41.
[http://dx.doi.org/10.1186/s13027-021-00381-4] [PMID: 34108031]
[53]
Cuellar-Gómez, H.; Ocharán-Hernández, M.; Calzada-Mendoza, C.; Comoto-Santacruz, D. Association of Fusobacterium nucleatum infec-tion and colorectal cancer: A mexican study. Rev. Gastroenterol. Mex., 2021, RGMXEN-720.
[54]
Yamaoka, Y.; Suehiro, Y.; Hashimoto, S.; Hoshida, T.; Fujimoto, M.; Watanabe, M.; Imanaga, D.; Sakai, K.; Matsumoto, T.; Nishioka, M.; Takami, T.; Suzuki, N.; Hazama, S.; Nagano, H.; Sakaida, I.; Yamasaki, T. Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population. J. Gastroenterol., 2018, 53(4), 517-524.
[http://dx.doi.org/10.1007/s00535-017-1382-6] [PMID: 28823057]
[55]
Kumar, R.; Herold, J.L.; Schady, D.; Davis, J.; Kopetz, S.; Martinez-Moczygemba, M.; Murray, B.E.; Han, F.; Li, Y.; Callaway, E.; Chap-kin, R.S.; Dashwood, W.M.; Dashwood, R.H.; Berry, T.; Mackenzie, C.; Xu, Y. Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. PLoS Pathog., 2017, 13(7), e1006440.
[http://dx.doi.org/10.1371/journal.ppat.1006440] [PMID: 28704539]
[56]
Castellarin, M.; Warren, R.L.; Freeman, J.D.; Dreolini, L.; Krzywinski, M.; Strauss, J.; Barnes, R.; Watson, P.; Allen-Vercoe, E.; Moore, R.A.; Holt, R.A. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res., 2012, 22(2), 299-306.
[http://dx.doi.org/10.1101/gr.126516.111] [PMID: 22009989]
[57]
Wu, N.; Yang, X.; Zhang, R.; Li, J.; Xiao, X.; Hu, Y.; Chen, Y.; Yang, F.; Lu, N.; Wang, Z.; Luan, C.; Liu, Y.; Wang, B.; Xiang, C.; Wang, Y.; Zhao, F.; Gao, G.F.; Wang, S.; Li, L.; Zhang, H.; Zhu, B. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb. Ecol., 2013, 66(2), 462-470.
[http://dx.doi.org/10.1007/s00248-013-0245-9] [PMID: 23733170]
[58]
Mira-Pascual, L.; Cabrera-Rubio, R.; Ocon, S.; Costales, P.; Parra, A.; Suarez, A.; Moris, F.; Rodrigo, L.; Mira, A.; Collado, M.C. Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal bi-omarkers. J. Gastroenterol., 2015, 50(2), 167-179.
[http://dx.doi.org/10.1007/s00535-014-0963-x] [PMID: 24811328]
[59]
Burns, M.B.; Lynch, J.; Starr, T.K.; Knights, D.; Blekhman, R. Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment. Genome Med., 2015, 7(1), 55.
[http://dx.doi.org/10.1186/s13073-015-0177-8] [PMID: 26170900]
[60]
Legakis, N.; Ioannides, H.; Tzannetis, S.; Golematis, B.; Papavassiliou, J. Faecal bacterial flora in patients with colon cancer and control subjects. Zentralblatt für Bakteriologie, Mikrobiologie und Hygiene 1 Abt Originale A, Medizinische Mikrobiologie. Infektionskrankheiten und Parasitologie, 1981, 251(1), 54-61.
[61]
Wang, T.; Cai, G.; Qiu, Y.; Fei, N.; Zhang, M.; Pang, X.; Jia, W.; Cai, S.; Zhao, L. Structural segregation of gut microbiota between colorec-tal cancer patients and healthy volunteers. ISME J., 2012, 6(2), 320-329.
[http://dx.doi.org/10.1038/ismej.2011.109] [PMID: 21850056]
[62]
Zeller, G.; Tap, J.; Voigt, A.Y.; Sunagawa, S.; Kultima, J.R.; Costea, P.I.; Amiot, A.; Böhm, J.; Brunetti, F.; Habermann, N.; Hercog, R.; Koch, M.; Luciani, A.; Mende, D.R.; Schneider, M.A.; Schrotz-King, P.; Tournigand, C.; Tran Van Nhieu, J.; Yamada, T.; Zimmermann, J.; Benes, V.; Kloor, M.; Ulrich, C.M.; von Knebel Doeberitz, M.; Sobhani, I.; Bork, P. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol. Syst. Biol., 2014, 10(11), 766.
[http://dx.doi.org/10.15252/msb.20145645] [PMID: 25432777]
[63]
Nakatsu, G.; Li, X.; Zhou, H.; Sheng, J.; Wong, S.H.; Wu, W.K.K.; Ng, S.C.; Tsoi, H.; Dong, Y.; Zhang, N.; He, Y.; Kang, Q.; Cao, L.; Wang, K.; Zhang, J.; Liang, Q.; Yu, J.; Sung, J.J. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat. Commun., 2015, 6(1), 8727.
[http://dx.doi.org/10.1038/ncomms9727] [PMID: 26515465]
[64]
Zhou, Y.; He, H.; Xu, H.; Li, Y.; Li, Z.; Du, Y.; He, J.; Zhou, Y.; Wang, H.; Nie, Y. Association of oncogenic bacteria with colorectal can-cer in South China. Oncotarget, 2016, 7(49), 80794-80802.
[http://dx.doi.org/10.18632/oncotarget.13094] [PMID: 27821805]
[65]
Dai, Z.; Coker, O.O.; Nakatsu, G.; Wu, W.K.K.; Zhao, L.; Chen, Z.; Chan, F.K.L.; Kristiansen, K.; Sung, J.J.Y.; Wong, S.H.; Yu, J. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome, 2018, 6(1), 70.
[http://dx.doi.org/10.1186/s40168-018-0451-2] [PMID: 29642940]
[66]
Iyadorai, T.; Mariappan, V.; Vellasamy, K.M.; Wanyiri, J.W.; Roslani, A.C.; Lee, G.K.; Sears, C.; Vadivelu, J. Prevalence and association of pks+ Escherichia coli with colorectal cancer in patients at the University Malaya Medical Centre, Malaysia. PLoS One, 2020, 15(1), e0228217.
[http://dx.doi.org/10.1371/journal.pone.0228217] [PMID: 31990962]
[67]
Rubinstein, M.R.; Wang, X.; Liu, W.; Hao, Y.; Cai, G.; Han, Y.W. Fusobacterium nucleatum promotes colorectal carcinogenesis by modu-lating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe, 2013, 14(2), 195-206.
[http://dx.doi.org/10.1016/j.chom.2013.07.012] [PMID: 23954158]
[68]
Zhang, S.; Cai, S.; Ma, Y. Association between Fusobacterium nucleatum and colorectal cancer: Progress and future directions. J. Cancer, 2018, 9(9), 1652-1659.
[http://dx.doi.org/10.7150/jca.24048] [PMID: 29760804]
[69]
Shang, F-M.; Liu, H-L. Fusobacterium nucleatum and colorectal cancer: A review. World J. Gastrointest. Oncol., 2018, 10(3), 71-81.
[http://dx.doi.org/10.4251/wjgo.v10.i3.71] [PMID: 29564037]
[70]
Luo, K.; Zhang, Y.; Xv, C.; Ji, J.; Lou, G.; Guo, X.; Chen, M.; Zhang, Y.; Wei, H.; Guo, M.; Huang, R.; Yu, S. Fusobacterium nucleatum, the communication with colorectal cancer. Biomed. Pharmacother., 2019, 116, 108988.
[http://dx.doi.org/10.1016/j.biopha.2019.108988] [PMID: 31112873]
[71]
Yang, Y.; Weng, W.; Peng, J.; Hong, L.; Yang, L.; Toiyama, Y.; Gao, R.; Liu, M.; Yin, M.; Pan, C. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating Toll-like receptor 4 signaling to nuclear Factor− κB, and up-regulating expression of microRNA-21. Gastroenterology, 2017, 152(4), 851-866. e824.
[72]
Li, C.; Zhao, L.; Chen, Y.; He, T.; Chen, X.; Mao, J.; Li, C.; Lyu, J.; Meng, Q.H. MicroRNA-21 promotes proliferation, migration, and invasion of colorectal cancer, and tumor growth associated with down-regulation of sec23a expression. BMC Cancer, 2016, 16(1), 605.
[http://dx.doi.org/10.1186/s12885-016-2628-z] [PMID: 27495250]
[73]
Gur, C.; Ibrahim, Y.; Isaacson, B.; Yamin, R.; Abed, J.; Gamliel, M.; Enk, J.; Bar-On, Y.; Stanietsky-Kaynan, N.; Coppenhagen-Glazer, S.; Shussman, N.; Almogy, G.; Cuapio, A.; Hofer, E.; Mevorach, D.; Tabib, A.; Ortenberg, R.; Markel, G.; Miklić, K.; Jonjic, S.; Brennan, C.A.; Garrett, W.S.; Bachrach, G.; Mandelboim, O. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity, 2015, 42(2), 344-355.
[http://dx.doi.org/10.1016/j.immuni.2015.01.010] [PMID: 25680274]
[74]
Wang, H-F.; Li, L-F.; Guo, S-H.; Zeng, Q-Y.; Ning, F.; Liu, W-L.; Zhang, G. Evaluation of antibody level against Fusobacterium nucleatum in the serological diagnosis of colorectal cancer. Sci. Rep., 2016, 6(1), 33440.
[http://dx.doi.org/10.1038/srep33440] [PMID: 27678333]
[75]
Yu, T.; Guo, F.; Yu, Y.; Sun, T.; Ma, D.; Han, J.; Qian, Y.; Kryczek, I.; Sun, D.; Nagarsheth, N. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell., 2017, 170, (3)548-563. e516.
[http://dx.doi.org/10.1016/j.cell.2017.07.008]
[76]
Sittipo, P.; Lobionda, S.; Choi, K.; Sari, I.N.; Kwon, H.Y.; Lee, Y.K. Toll-like receptor 2-mediated suppression of colorectal cancer patho-genesis by polysaccharide A from Bacteroides fragilis. Front. Microbiol., 2018, 9, 1588.
[http://dx.doi.org/10.3389/fmicb.2018.01588] [PMID: 30065713]
[77]
Butt, J.; Jenab, M.; Werner, J.; Fedirko, V.; Weiderpass, E.; Dahm, C.C.; Tjønneland, A.; Olsen, A.; Boutron-Ruault, M-C.; Rothwell, J.A.; Severi, G.; Kaaks, R.; Turzanski-Fortner, R.; Aleksandrova, K.; Schulze, M.; Palli, D.; Pala, V.; Panico, S.; Tumino, R.; Sacerdote, C. Bue-no-de-Mesquita, B.; Van Gils, C.H.; Gram, I.T.; Lukic, M.; Sala, N.; Sánchez Pérez, M.J.; Ardanaz, E.; Chirlaque, M.D.; Palmquist, R.; Löwenmark, T.; Travis, R.C.; Heath, A.; Cross, A.J.; Freisling, H.; Zouiouich, S.; Aglago, E.; Waterboer, T.; Hughes, D.J. Association of Pre-diagnostic Antibody Responses to Escherichia coli and Bacteroides fragilis Toxin Proteins with Colorectal Cancer in a European Co-hort. Gut Microbes, 2021, 13(1), 1-14.
[http://dx.doi.org/10.1080/19490976.2021.1903825] [PMID: 33874856]
[78]
Xie, X.; Jiang, D.; Zhou, X.; Ye, X.; Yang, P.; He, Y. Recombinant Bacteroides fragilis enterotoxin-1 (rBFT-1) promotes proliferation of colorectal cancer via CCL3-related molecular pathways. Open Life Sci., 2021, 16(1), 408-418.
[http://dx.doi.org/10.1515/biol-2021-0043] [PMID: 33981848]
[79]
Zhang, J.; Lu, X.; Zhao, G.; Shi, H.; Geng, Y.; Zhong, W.; Dong, L. Relationships between the enrichment of ETBF, Fn, Hp in intestinal and colorectal cancer. Chin. J. Oncol., 2018, 40(2), 99-104.
[80]
Boleij, A.; Hechenbleikner, E.M.; Goodwin, A.C.; Badani, R.; Stein, E.M.; Lazarev, M.G.; Ellis, B.; Carroll, K.C.; Albesiano, E.; Wick, E.C.; Platz, E.A.; Pardoll, D.M.; Sears, C.L. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer pa-tients. Clin. Infect. Dis., 2015, 60(2), 208-215.
[http://dx.doi.org/10.1093/cid/ciu787] [PMID: 25305284]
[81]
Purcell, R.V.; Pearson, J.; Frizelle, F.A.; Keenan, J.I. Comparison of standard, quantitative and digital PCR in the detection of enterotoxi-genic Bacteroides fragilis. Sci. Rep., 2016, 6(1), 34554.
[http://dx.doi.org/10.1038/srep34554] [PMID: 27686415]
[82]
Toprak, N.U.; Yagci, A.; Gulluoglu, B.M.; Akin, M.L.; Demirkalem, P.; Celenk, T.; Soyletir, G. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin. Microbiol. Infect., 2006, 12(8), 782-786.
[http://dx.doi.org/10.1111/j.1469-0691.2006.01494.x] [PMID: 16842574]
[83]
Viljoen, K.S.; Dakshinamurthy, A.; Goldberg, P.; Blackburn, J.M. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer. PLoS One, 2015, 10(3), e0119462.
[http://dx.doi.org/10.1371/journal.pone.0119462] [PMID: 25751261]
[84]
Wu, S.; Morin, P.J.; Maouyo, D.; Sears, C.L. Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology, 2003, 124(2), 392-400.
[http://dx.doi.org/10.1053/gast.2003.50047] [PMID: 12557145]
[85]
Wu, S.; Rhee, K-J.; Albesiano, E.; Rabizadeh, S.; Wu, X.; Yen, H-R.; Huso, D.L.; Brancati, F.L.; Wick, E.; McAllister, F.; Housseau, F.; Pardoll, D.M.; Sears, C.L. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med., 2009, 15(9), 1016-1022.
[http://dx.doi.org/10.1038/nm.2015] [PMID: 19701202]
[86]
Wick, E.C.; Rabizadeh, S.; Albesiano, E.; Wu, X.; Wu, S.; Chan, J.; Rhee, K-J.; Ortega, G.; Huso, D.L.; Pardoll, D.; Housseau, F.; Sears, C.L. Stat3 activation in murine colitis induced by enterotoxigenic Bacteroides fragilis. Inflamm. Bowel Dis., 2014, 20(5), 821-834.
[http://dx.doi.org/10.1097/MIB.0000000000000019] [PMID: 24704822]
[87]
Babbar, N.; Casero, R.A., Jr Tumor necrosis factor-α increases reactive oxygen species by inducing spermine oxidase in human lung epi-thelial cells: A potential mechanism for inflammation-induced carcinogenesis. Cancer Res., 2006, 66(23), 11125-11130.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-3174] [PMID: 17145855]
[88]
Battaglia, V.; DeStefano Shields, C.; Murray-Stewart, T.; Casero, R.A., Jr Polyamine catabolism in carcinogenesis: Potential targets for chemotherapy and chemoprevention. Amino Acids, 2014, 46(3), 511-519.
[http://dx.doi.org/10.1007/s00726-013-1529-6] [PMID: 23771789]
[89]
Keenan, J.I.; Frizelle, F.A. Bacteria flying under the radar: Linking a bacterial infection to colon carcinogenesis. Infect. Agent. Cancer, 2014, 9(1), 31.
[http://dx.doi.org/10.1186/1750-9378-9-31] [PMID: 25225573]
[90]
Wassenaar, T.M.E.E. coli and colorectal cancer: A complex relationship that deserves a critical mindset. Crit. Rev. Microbiol., 2018, 44(5), 619-632.
[http://dx.doi.org/10.1080/1040841X.2018.1481013] [PMID: 29909724]
[91]
Amarsy, R.; Guéret, D.; Benmansour, H.; Flicoteaux, R.; Berçot, B.; Meunier, F.; Mougari, F.; Jacquier, H.; Pean de Ponfilly, G.; Clermont, O.; Denamur, E.; Teixeira, A.; Cambau, E. Determination of Escherichia coli phylogroups in elderly patients with urinary tract infection or asymptomatic bacteriuria. Clin. Microbiol. Infect., 2019, 25(7), 839-844.
[http://dx.doi.org/10.1016/j.cmi.2018.12.032] [PMID: 30648603]
[92]
Buc, E.; Dubois, D.; Sauvanet, P.; Raisch, J.; Delmas, J.; Darfeuille-Michaud, A.; Pezet, D.; Bonnet, R. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One, 2013, 8(2), e56964.
[http://dx.doi.org/10.1371/journal.pone.0056964] [PMID: 23457644]
[93]
Raisch, J.; Buc, E.; Bonnet, M.; Sauvanet, P.; Vazeille, E.; de Vallée, A.; Déchelotte, P.; Darcha, C.; Pezet, D.; Bonnet, R.; Bringer, M.A.; Darfeuille-Michaud, A. Colon cancer-associated B2 Escherichia coli colonize gut mucosa and promote cell proliferation. World J. Gastroenterol., 2014, 20(21), 6560-6572.
[http://dx.doi.org/10.3748/wjg.v20.i21.6560] [PMID: 24914378]
[94]
Martin, H.M.; Campbell, B.J.; Hart, C.A.; Mpofu, C.; Nayar, M.; Singh, R.; Englyst, H.; Williams, H.F.; Rhodes, J.M. Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer. Gastroenterology, 2004, 127(1), 80-93.
[http://dx.doi.org/10.1053/j.gastro.2004.03.054] [PMID: 15236175]
[95]
Prorok-Hamon, M.; Friswell, M.K.; Alswied, A.; Roberts, C.L.; Song, F.; Flanagan, P.K.; Knight, P.; Codling, C.; Marchesi, J.R.; Winstan-ley, C.; Hall, N.; Rhodes, J.M.; Campbell, B.J. Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer. Gut, 2014, 63(5), 761-770.
[http://dx.doi.org/10.1136/gutjnl-2013-304739] [PMID: 23846483]
[96]
Faïs, T.; Delmas, J.; Barnich, N.; Bonnet, R.; Dalmasso, G. Colibactin: More than a new bacterial toxin. Toxins (Basel), 2018, 10(4), 151.
[http://dx.doi.org/10.3390/toxins10040151] [PMID: 29642622]
[97]
Borges-Canha, M.; Portela-Cidade, J.P.; Dinis-Ribeiro, M.; Leite-Moreira, A.F.; Pimentel-Nunes, P. Role of colonic microbiota in colorectal carcinogenesis: A systematic review. Rev. Esp. Enferm. Dig., 2015, 107(11), 659-671.
[http://dx.doi.org/10.17235/reed.2015.3830/2015] [PMID: 26541655]
[98]
Payros, D.; Secher, T.; Boury, M.; Brehin, C.; Ménard, S.; Salvador-Cartier, C.; Cuevas-Ramos, G.; Watrin, C.; Marcq, I.; Nougayrède, J-P.; Dubois, D.; Bedu, A.; Garnier, F.; Clermont, O.; Denamur, E.; Plaisancié, P.; Theodorou, V.; Fioramonti, J.; Olier, M.; Oswald, E. Ma-ternally acquired genotoxic Escherichia coli alters offspring’s intestinal homeostasis. Gut Microbes, 2014, 5(3), 313-325.
[http://dx.doi.org/10.4161/gmic.28932] [PMID: 24971581]
[99]
Park, C.H.; Eun, C.S.; Han, D.S. Intestinal microbiota, chronic inflammation, and colorectal cancer. Intest. Res., 2018, 16(3), 338-345.
[http://dx.doi.org/10.5217/ir.2018.16.3.338] [PMID: 30090032]
[100]
Arthur, J.C.; Perez-Chanona, E.; Mühlbauer, M.; Tomkovich, S.; Uronis, J.M.; Fan, T-J.; Campbell, B.J.; Abujamel, T.; Dogan, B.; Rogers, A.B.; Rhodes, J.M.; Stintzi, A.; Simpson, K.W.; Hansen, J.J.; Keku, T.O.; Fodor, A.A.; Jobin, C. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science, 2012, 338(6103), 120-123.
[http://dx.doi.org/10.1126/science.1224820] [PMID: 22903521]
[101]
Johnson, J.R.; Johnston, B.; Kuskowski, M.A.; Nougayrede, J-P.; Oswald, E. Molecular epidemiology and phylogenetic distribution of the Escherichia coli pks genomic island. J. Clin. Microbiol., 2008, 46(12), 3906-3911.
[http://dx.doi.org/10.1128/JCM.00949-08] [PMID: 18945841]
[102]
Shimpoh, T.; Hirata, Y.; Ihara, S.; Suzuki, N.; Kinoshita, H.; Hayakawa, Y.; Ota, Y.; Narita, A.; Yoshida, S.; Yamada, A.; Koike, K.; Ihara, S.; Suzuki, N.; Kinoshita, H.; Hayakawa, Y.; Ota, Y.; Narita, A.; Yoshida, S.; Yamada, A. Prevalence of pks-positive Escherichia coli in Japanese patients with or without colorectal cancer. Gut Pathog., 2017, 9(1), 1-8.
[http://dx.doi.org/10.1186/s13099-017-0185-x]
[103]
Secher, T.; Samba-Louaka, A.; Oswald, E.; Nougayrède, J-P. Escherichia coli producing colibactin triggers premature and transmissible senescence in mammalian cells. PLoS One, 2013, 8(10), e77157.
[http://dx.doi.org/10.1371/journal.pone.0077157] [PMID: 24116215]
[104]
Cougnoux, A.; Dalmasso, G.; Martinez, R.; Buc, E.; Delmas, J.; Gibold, L.; Sauvanet, P.; Darcha, C.; Déchelotte, P.; Bonnet, M.; Pezet, D.; Wodrich, H.; Darfeuille-Michaud, A.; Bonnet, R. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut, 2014, 63(12), 1932-1942.
[http://dx.doi.org/10.1136/gutjnl-2013-305257] [PMID: 24658599]
[105]
Iftekhar, A.; Berger, H.; Bouznad, N.; Heuberger, J.; Boccellato, F.; Dobrindt, U.; Hermeking, H.; Sigal, M.; Meyer, T.F. Genomic aberra-tions after short-term exposure to colibactin-producing E. coli transform primary colon epithelial cells. Nat. Commun., 2021, 12(1), 1003.
[http://dx.doi.org/10.1038/s41467-021-21162-y] [PMID: 33579932]
[106]
Salesse, L.; Lucas, C.; Hoang, M.H.T.; Sauvanet, P.; Rezard, A.; Rosenstiel, P.; Damon-Soubeyrand, C.; Barnich, N.; Godfraind, C.; Dal-masso, G.; Nguyen, H.T.T. Colibactin-Producing Escherichia coli Induce the Formation of Invasive Carcinomas in a Chronic Inflamma-tion-Associated Mouse Model. Cancers (Basel), 2021, 13(9), 2060.
[http://dx.doi.org/10.3390/cancers13092060] [PMID: 33923277]
[107]
Gao, R.; Gao, Z.; Huang, L.; Qin, H. Gut microbiota and colorectal cancer. Eur. J. Clin. Microbiol. Infect. Dis., 2017, 36(5), 757-769.
[http://dx.doi.org/10.1007/s10096-016-2881-8] [PMID: 28063002]
[108]
Perillo, F.; Amoroso, C.; Strati, F.; Giuffrè, M.R.; Díaz-Basabe, A.; Lattanzi, G.; Facciotti, F. Gut microbiota manipulation as a tool for colorectal cancer management: Recent advances in its use for therapeutic purposes. Int. J. Mol. Sci., 2020, 21(15), 5389.
[http://dx.doi.org/10.3390/ijms21155389] [PMID: 32751239]
[109]
Huang, K.; Wu, L.; Yang, Y. Gut microbiota: An emerging biological diagnostic and treatment approach for gastrointestinal diseases. JGH Open, 2021, 5(9), 973-975.
[http://dx.doi.org/10.1002/jgh3.12659] [PMID: 34584963]
[110]
Kaźmierczak-Siedlecka, K.; Daca, A.; Fic, M.; van de Wetering, T.; Folwarski, M.; Makarewicz, W. Therapeutic methods of gut microbiota modification in colorectal cancer management - fecal microbiota transplantation, prebiotics, probiotics, and synbiotics. Gut Microbes, 2020, 11(6), 1518-1530.
[http://dx.doi.org/10.1080/19490976.2020.1764309] [PMID: 32453670]
[111]
Raman, M.; Ambalam, P.; Kondepudi, K.K.; Pithva, S.; Kothari, C.; Patel, A.T.; Purama, R.K.; Dave, J.M.; Vyas, B.R. Potential of probiot-ics, prebiotics and synbiotics for management of colorectal cancer. Gut Microbes, 2013, 4(3), 181-192.
[http://dx.doi.org/10.4161/gmic.23919] [PMID: 23511582]
[112]
Chen, D.; Wu, J.; Jin, D.; Wang, B.; Cao, H. Fecal microbiota transplantation in cancer management: Current status and perspectives. Int. J. Cancer, 2019, 145(8), 2021-2031.
[http://dx.doi.org/10.1002/ijc.32003] [PMID: 30458058]
[113]
Keku, T.O.; Dulal, S.; Deveaux, A.; Jovov, B.; Han, X. The gastrointestinal microbiota and colorectal cancer. Am. J. Physiol. Gastrointest. Liver Physiol., 2015, 308(5), G351-G363.
[http://dx.doi.org/10.1152/ajpgi.00360.2012] [PMID: 25540232]
[114]
Yang, J.; Yu, J. The association of diet, gut microbiota and colorectal cancer: What we eat may imply what we get. Protein Cell, 2018, 9(5), 474-487.
[http://dx.doi.org/10.1007/s13238-018-0543-6] [PMID: 29713943]
[115]
Tripathy, A.; Dash, J.; Kancharla, S.; Kolli, P.; Mahajan, D.; Senapati, S.; Jena, M.K. Probiotics: A promising candidate for management of colorectal cancer. Cancers (Basel), 2021, 13(13), 3178.
[http://dx.doi.org/10.3390/cancers13133178] [PMID: 34202265]
[116]
Torres-Maravilla, E.; Boucard, A-S.; Mohseni, A.H.; Taghinezhad-S, S.; Cortes-Perez, N.G.; Bermúdez-Humarán, L.G. Role of gut micro-biota and probiotics in colorectal cancer: Onset and progression. Microorganisms, 2021, 9(5), 1021.
[http://dx.doi.org/10.3390/microorganisms9051021] [PMID: 34068653]
[117]
Ljungh, A.; Wadström, T. Lactic acid bacteria as probiotics. Curr. Issues Intest. Microbiol., 2006, 7(2), 73-89.
[PMID: 16875422]
[118]
Zhong, L.; Zhang, X.; Covasa, M. Emerging roles of lactic acid bacteria in protection against colorectal cancer. World J. Gastroenterol., 2014, 20(24), 7878-7886.
[http://dx.doi.org/10.3748/wjg.v20.i24.7878] [PMID: 24976724]
[119]
Saeed, M.; Shoaib, A.; Kandimalla, R.; Javed, S.; Almatroudi, A.; Gupta, R.; Aqil, F. Microbe-based therapies for colorectal cancer: Ad-vantages and limitations. Semin. Cancer Biol., 2021.